Form D · Biotechnology

NEXEON MEDSYSTEMS INC

Dallas, TX · CIK 0001416172

Offering snapshot reported Jul 20, 2017 · SEC filing

Reported sold
$1.17M
Offering amount: $2M
Investors reported
15
Form D · investor count
Minimum accepted
$10K
Reported outside-investor minimum
First sale
Apr 21, 2017
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$583K$1.17MMay 4, 2017: $135,000.00May 4, 2017Jul 20, 2017: $1,165,000.00Jul 20, 2017

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$135,000 → $1,165,000
  • Reported investors2 → 15

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jul 20, 2017Amendment$1,165,000$1,030,000vs May 4, 201715SEC filing
May 4, 2017Initial$135,000No comparison2SEC filing
Dec 5, 2016Amendment$4,278,510$3,150,437vs Apr 13, 201642SEC filing
Apr 13, 2016Initial$1,128,073No comparison0SEC filing
Apr 29, 2010InitialYet to sellNo comparison0SEC filing
Jan 16, 2009PaperNot reportedNo comparisonNot reportedSEC filing
Oct 22, 2007PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-286011
Total offering amount was $2,000,000 plus a $500,000 over-allotment option. Total sold was $1,165,000. The offering closed on July 20, 2017.

Source: Form D, filed Jul 20, 2017. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Ralph L. Ballard, Iii Director
Mark C. Bartell Director
Mark C Bates Director, Executive
Brian Blischak Executive
Bret Lee Chandler Executive
Ronald Conquest Director, Executive
Kent J George Director
W. Henry Harmon Director
Dan Heilbrunn Executive
Christopher R Miller Executive
J. Holmes Morrison Director
Michael Neitzel Director
Daniel P. Powell Executive
William M Rosellini Director, Executive
Kent Stalker Executive
Robert A Stern Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
1910 Pacific Avenue, Suite 20000
Dallas, TX, 75201